Kardigan, a Phase 2b/3 biotech developing therapies for cardiovascular diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Kardigan is advancing three late-stage product candidates: danicamtiv, an oral cardiac myosin activator in a Phase 2b/3 trial for genetic dilated cardiomyopathy caused by MYH7 and TTN gene variants; ataciguat, an oral soluble guanylate cyclase activator in a Phase 2b trial targeting calcific aortic valve stenosis progression; and tonlamarsen, a subcutaneous antisense oligonucleotide administered once monthly that targets hepatic angiotensinogen for blood pressure management in post-hospitalization acute severe hypertension. Kardigan also operates the Prolaio platform, a proprietary data and analytics system incorporating FDA-cleared algorithms and wearable sensor integration designed to collect continuous real-world physiologic data from patients during clinical trials.
The Princeton, NJ-based company was founded in 2023 and plans to list on the Nasdaq under the symbol KARD. Kardigan filed confidentially on March 26, 2026. J.P. Morgan, Jefferies, Leerink Partners, and TD Cowen are the joint bookrunners on the deal.
